Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01460381 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Genotype on LY2216684
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01460381 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 18 participants.
The verdict
NCT01460381, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The study will evaluate how genetic profiles respond to LY2216684 and the effect of Quinidine on the pharmacokinetics (PK) of LY2216684 in a specific genetic profile. Side effects will be documented.
Interventions
- DRUG LY2216684
- DRUG Quinidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-10 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01460381
The ClinicalTrials.gov registry entry for NCT01460381 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LY2216684 is the first listed.
NCT01460381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01460381 about?
NCT01460381 is a clinical study titled "A Study to Evaluate the Effect of Genotype on LY2216684". The study will evaluate how genetic profiles respond to LY2216684 and the effect of Quinidine on the pharmacokinetics (PK) of LY2216684 in a specific genetic profile. Side effects will be documented.
What is the current status of trial NCT01460381?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2011-10. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01460381?
The interventions under investigation include: LY2216684 (DRUG), Quinidine (DRUG).
Who is sponsoring clinical trial NCT01460381?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.